SCHEMBL2065640

SCHEMBL2065640

O=C1NC(=S)S/C1=C/c1cc(Br)ccc1OCc1ccccc1Cl

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
PTP4A3 O75365 10/20 1.00
MEN1 O00255 1/20 0.61
POLB P06746 1/20 0.61
DNMT1 P26358 1/20 0.61
BLM P54132 1/20 0.61
KMT2A Q03164 1/20 0.61
PTPN1 P18031 3/20 0.60
PIM1 P11309 1/20 0.56
GSK3B P49841 1/20 0.55
DUSP4 Q13115 1/20 0.54
PTP4A1 Q93096 1/20 0.54
MGAM O43451 1/20 0.53
GAA P10253 1/20 0.53
SI P14410 1/20 0.53
MGAM2 Q2M2H8 1/20 0.53
ADAMTS5 Q9UNA0 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2181282 1.00 PTP4A3 (1.00) PTP4A3MEN1POLBDNMT1BLM
SCHEMBL2065642 1.00 PTP4A3 (1.00) PTP4A3MEN1POLBDNMT1BLM
SCHEMBL2066174 0.90 PTP4A3 (1.00) PTP4A3PTPN1GSK3BADAMTS5
SCHEMBL10090207 0.90 PTP4A3 (1.00) PTP4A3PTPN1GSK3BADAMTS5
SCHEMBL2066172 0.90 PTP4A3 (1.00) PTP4A3PTPN1GSK3BADAMTS5
SCHEMBL2066086 0.89 PTP4A3 (0.80) PTP4A3MEN1POLBDNMT1BLM
SCHEMBL2066087 0.89 PTP4A3 (0.80) PTP4A3MEN1POLBDNMT1BLM
SCHEMBL10090198 0.89 PTP4A3 (0.80) PTP4A3MEN1POLBDNMT1BLM
SCHEMBL10090222 0.88 PTP4A3 (0.81) PTP4A3MEN1POLBKMT2APTPN1
SCHEMBL2066459 0.88 PTP4A3 (0.81) PTP4A3MEN1POLBKMT2APTPN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8148541-B2 Rhodanine derivatives, a process for the preparation thereof and pharmaceutical composition containing the same KOREA RESEARCH INSTITUTE OF BIOSCIENCE AND BIOTECHNOLOGY (KR) 2012-04-03 US claimed
US-20090042872-A1 Rhodanine Derivatives, a Process for the Preparation Thereof and Pharmaceutical Composition Containing the Same KOREA RESEARCH INSTITUTE OF BIOSCIENCE AND BIOTECHNOLOGY (KR) 2009-02-12 US claimed
US-8148541-B2 Rhodanine derivatives, a process for the preparation thereof and pharmaceutical composition containing the same KOREA RESEARCH INSTITUTE OF BIOSCIENCE AND BIOTECHNOLOGY (KR) 2012-04-03 US disclosed
US-20090042872-A1 Rhodanine Derivatives, a Process for the Preparation Thereof and Pharmaceutical Composition Containing the Same KOREA RESEARCH INSTITUTE OF BIOSCIENCE AND BIOTECHNOLOGY (KR) 2009-02-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090042872-A1 Rhodanine Derivatives, a Process for the Preparation Thereof and Pharmaceutical Composition Containing the Same PTPRR, PTPRG, PTPRS PTP4A3 28/4885MEN1 4202/4885POLB 2580/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.